Methods of treating an eye disorder

A method of improving perfusion of an eye, the method comprising:

• identifying a subject with non-proliferative DR;
• and
• administering an initial dose of an anti-VEGF antibody conjugate to the subject, to provide improved perfusion in at least one eye.

A method of treating a subject with DME, DR or RVO, the method comprising:

• administering 1-3 loading doses of an anti-VEGF antibody conjugate to a subject with DME, DR or RVO;
• not administering more than 3 loading doses to the subject;
• providing a follow-on application of the anti-VEGF antibody conjugate at a point in time no sooner than 12 weeks after a last loading dose or after a last follow-on application of the anti-VEGF antibody conjugate, wherein the loading doses are administered to the subject on a monthly basis.

A method of treating a subject with RVO, the method comprising:

• administering 1 or 2 loading doses of an anti-VEGF antibody conjugate to a subject with RVO;
• not administering more than 2 loading doses to the subject;
• providing a follow-on administration of the anti-VEGF antibody conjugate at a point in time no sooner than 8 weeks after a last loading dose, wherein the loading doses are administered to the subject on a monthly basis.

The method of any one of claims 35 to 38 or 45 to 77, wherein each loading dose of the anti-VEGF antibody conjugate comprises at least 1.25 mg of antibody protein.

The method of any one of claims 1-39 or 45-77, wherein the anti-VEGF antibody conjugate is administered via intravitreal injection.

The method of any one of claims 1-37 or 45-77, wherein the anti-VEGF antibody conjugate is administered at an amount of 5 mg.

The method of any one of claims 1-38 or 45-77, wherein the anti-VEGF antibody conjugate comprises:

• an antibody conjugate comprising an anti-VEGF-A immunoglobulin G (IgG) bonded to a polymer, which polymer comprises MPC monomers, wherein the sequence of the anti-VEGF-A antibody heavy chain is SEQ ID NO:
• 1, and the sequence of the anti-VEGF-A antibody light chain is SEQ ID NO. 2, and wherein the antibody is bonded at C449 in SEQ ID NO. 1 to the polymer.

A method of treating RVO, wherein the method comprises:

• administering an anti-VEGF antibody conjugate to a subject in need of treating RVO at 1-3 loading doses;
• and
• whereby the subject retains a therapeutic result of the anti-VEGF antibody conjugate therapy for RVO for at least 8 weeks after a final loading dose and/or for one or more subsequent dosing intervals of at least 8 weeks.

A method of disease modification of an eye disorder, wherein the method comprises:

• administering an anti-VEGF antibody conjugate to a subject having an eye disorder at a first loading dose,
• whereby the eye disorder is thereby modified in a beneficial manner to the subject.

A method of treating an eye disorder, comprising:

• administering an anti-VEGF antibody conjugate to a subject in need of treating an eye disorder at a first loading dose, wherein the eye disorder is diabetic macular edema (DME);
• and
• repeating the loading dose at least once, but not more than twice, whereby the subject retains a therapeutic result of the anti-VEGF antibody conjugate therapy for at least 8 weeks after a final loading dose.

A method of treating an eye disorder, comprising administering to a subject in need of treating an eye disorder a therapeutically effective amount of the anti-VEGF antibody conjugate at a dosing schedule of Q12W or longer, wherein the eye disorder is diabetic retinopathy (DR), thereby treating the eye disorder.

A method of treating an eye disorder, comprising administering to a subject in need of treating an eye disorder a first dose of an anti-VEGF antibody conjugate of a plurality of doses of the anti-VEGF antibody conjugate in a dosing schedule comprising:

• a loading dosing schedule comprising 1-3 loading doses of the anti-VEGF antibody conjugate, wherein the first dose is a loading dose;
• followed by
• a maintenance dosing schedule comprising one or more subsequent doses of the anti-VEGF antibody conjugate after a final loading dose, wherein the maintenance dosing schedule comprises a predetermined dosing schedule of Q8W or longer.

A method of treating an eye disorder, comprising:

• identifying a subject in need of treating an eye disorder, wherein the eye disorder is presumed ocular histoplasmosis syndrome;
• and
• intravitreally administering to the subject a therapeutically effective amount of the anti-VEGF antibody conjugate, thereby treating the eye disorder.